1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Oxford BioDynamics Plc

Oxford BioDynamics Plc

0.11
GBX
0.00
(0.00%)
823.85MMarket Cap
Jan 26Next Earn
Oxford BioDynamics Plc
LSE:OBD
(London Stock Exchange)

Recent

price

0.11

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
GBP
0.03
0.05
0.01
0.01
0.01
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.08
-0.06
-0.01
-0.02
-0.04
-0.02
-0.03
-0.05
-0.07
-0.07
-0.07
-0.05
-0.01
- -
Basic EPS, GAAP
0.01
-0.04
-0.02
-0.02
-0.02
-0.03
-0.03
-0.04
-0.1
-0.06
-0.06
-0.04
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.03
0.06
0.1
0.09
0.13
0.22
0.19
0.14
0.07
0.03
0.03
0.01
- -
- -
Book Value per Share
0.03
0.06
0.1
0.09
0.13
0.21
0.18
0.13
0.06
0.01
0.02
0.01
- -
- -
Tangible Book Value per Share
13
13
86
82
85
88
93
93
93
100
147
256
1,387
2,881
Basic Weighted Avg Shares
- -
1
1
1
1
1
1
- -
- -
- -
1
1
1
- -
Sales/Revenue/Turnover
-311.14
-116.08
-229.06
-172.41
-212.43
-219.39
-410.47
-1,085.75
-2,202.93
-5,585.06
-1,993.73
-1,886.48
-981.46
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
- -
Depreciation Expense
-1
-1
-1
-2
-4
-2
-3
-4
-7
-7
-11
-12
-11
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-301.43
-111.68
-143.16
-158.57
-321.56
-164.67
-308.71
-953.73
-1,959.53
-4,357.14
-2,122.75
-1,818.71
-1,018.54
- -
Profit Margin (%)
3
5
9
7
11
19
16
12
4
- -
3
2
- -
2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
6
5
6
5
4
3
LT Debt
3
5
9
8
12
20
17
13
7
3
6
4
1
3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-18.08
-14.11
-20.65
-39.42
-12.36
-15.05
-28.68
-67.44
-144.86
-250.51
-222.16
-407.49
- -
Return on Common Equity (%)

Capital Structure

GBP

•

in mil. unless spec.
Mar'25
Sep'25
Mar'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
4
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,958
1,958
4,291
Market Capitalization
9
9
8

Working Capital

GBP

•

in mil. unless spec.
Mar'25
Sep'25
Mar'26
Total Current Assets
7
2
4
Cash, Cash Equivalents & STI
4
1
3
Accounts Receivable, Net
1
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
3
3
2
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.83%
-15.79%
-74.39%
Free Cash Flow
23.45%
28.26%
-27.4%
Net Income, GAAP
36.07%
23.73%
-3.58%
Sales/Revenue/Turnover
23.88%
49.6%
72.17%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1
2025
- -
- -
1
2026
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.05
2025
- -
- -
-0.01
2026
- -
- -
- -

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Oxford BioDynamics Plc is a United Kingdom-based biotechnology company that advances personalized healthcare through the development and commercialization of precision medicine tests based on its proprietary EpiSwitch platform, which enables 3D genomics for clinical applications in diagnostics and biomarker research. The company offers a portfolio of clinical smart tests including EpiSwitch CiRT, a blood-based Checkpoint Inhibitor Response Test that predicts patient responses to immunotherapy for cancer treatment; EpiSwitch PSE, a prognostic screening test for prostate cancer risk; EpiSwitch Explorer, a microarray kit for high-throughput 3D genome profiling and biomarker discovery; and Specimen Submission Kits for sample collection, partnering with CLIA-certified labs to deliver these to physicians worldwide. Founded in 2007 and headquartered at 3140 Rowan Place, John Smith Drive, Oxford Business Park South, Oxford, OX4 2WB, United Kingdom, it maintains operations including offices and labs in Oxford, UK; Gaithersburg and Frederick, Maryland, USA; and an ISO-certified laboratory in Penang, Malaysia, targeting healthcare providers, pharmaceutical companies, and patients with life-changing diseases such as cancer. Recent developments include a commercial agreement in January 2025 with Romania's Regina Maria Private Health Network to expand EpiSwitch PSE distribution; a strategic fundraising of £7 million in November 2025 via placing and subscriptions to support commercialization and partnerships; initiation of cost-saving measures and a strategic review in October 2024; a new partnership with Google Cloud advancing platform capabilities; and ongoing discussions for licensing and collaborations with large pharmaceutical, biotech, and diagnostic firms to monetize its assets including over 40 prior partnerships with entities like Pfizer, Roche, and Genentech.

Company News

Company News APIChatGPT